Cargando…

Striatal Dopamine D(2) Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia

BACKGROUND: Transdermal antipsychotic patch formulations offer potential benefits, including improved adherence. This study investigated the striatal dopamine D(2) receptor occupancy with daily blonanserin transdermal patch application. METHODS: This open-label, phase II study enrolled 18 Japanese o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishibe, Hironori, Tateno, Amane, Sakayori, Takeshi, Yamamoto, Masahiro, Kim, WooChan, Kakuyama, Hiroyoshi, Okubo, Yoshiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883894/ https://www.ncbi.nlm.nih.gov/pubmed/32936897 http://dx.doi.org/10.1093/ijnp/pyaa071

Ejemplares similares

Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D(2) Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch
por: Tomita, Yoshiko, et al.
Publicado: (2022)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

Comparison of Dopamine D(3) and D(2) Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [(11)C]-(+)-PHNO
por: Tateno, Amane, et al.
Publicado: (2018)

Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
por: Sakai, Shintaro, et al.
Publicado: (2021)

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch
por: Hagikura, Minako, et al.
Publicado: (2023)

Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [(18)F]FE-PE2I
por: Nogami, Tsuyoshi, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Effect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserinEffect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing blonanserinretain-->
por: Zhao, Chunyi, et al.
Publicado: (2016)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin, Tomomi, et al.
Publicado: (2013)

Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan
por: Tateno, Amane, et al.
Publicado: (2017)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Multi-Atlas MRI-Based Striatum Segmentation for (123)I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome
por: Sohara, Koji, et al.
Publicado: (2021)

Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2017)

PM429. Comparison of haloperidol and blonanserin on development of dopamine supersensitivity after chronic treatment
por: Hashimoto, Takashi, et al.
Publicado: (2016)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Optogenetic stimulation of striatal patches modifies habit formation and inhibits dopamine release
por: Nadel, J. A., et al.
Publicado: (2021)

Abnormal Striatal Dopamine Transmission in Schizophrenia
por: Brunelin, Jerome, et al.
Publicado: (2013)

Influence of contact with schizophrenia on implicit attitudes towards schizophrenia patients held by clinical residents
por: Omori, Ataru, et al.
Publicado: (2012)

Striatal dopamine, reward, and decision making in schizophrenia
por: Deserno, Lorenz, et al.
Publicado: (2016)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases
por: Min, Aran, et al.
Publicado: (2013)

Simple and Sensitive Analysis of Blonanserin and Blonanserin C in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry and Its Application
por: Zheng, Yunliang, et al.
Publicado: (2014)

Suicide decline and improved psychiatric treatment status: longitudinal survey of suicides and serious suicide attempters in Tokyo
por: Otaka, Yasushi, et al.
Publicado: (2022)

Striatal Dopamine Release in Schizophrenia Comorbid with Substance Dependence
por: Thompson, Judy L., et al.
Publicado: (2012)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Pharmacokinetics of transdermal buprenorphine patch in the elderly
por: Al-Tawil, Nabil, et al.
Publicado: (2012)

Transdermal iontophoresis patch with reverse electrodialysis
por: Lee, Joon, et al.
Publicado: (2017)

Stimuli-responsive transdermal microneedle patches
por: Makvandi, Pooyan, et al.
Publicado: (2021)

Wearable patches for transdermal drug delivery
por: He, Jiahui, et al.
Publicado: (2023)

A case of delusional parasitosis responded to blonanserin
por: Rathi, Anubhav, et al.
Publicado: (2018)

Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2019)

S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA
por: Kim, Seoyoung, et al.
Publicado: (2018)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Formulation development and investigation of domperidone transdermal patches
por: Prabhu, Prabhakar, et al.
Publicado: (2011)

Fungal Endocarditis Secondary to Transdermal Fentanyl Patch
por: Casey, Bradley, et al.
Publicado: (2023)

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
por: Hori, Hikaru, et al.
Publicado: (2014)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4divv8ngfb0tnukgocqc7n6t90